Alkermes Reported More Revenue Than Expected. Here’s Why the Stock Is Falling.

Barrons | Feb 14, 2020 at 3:46 PM
  • It looks like investors may be running out of patience with Alkermes, a biotech with drugs on the market to treat alcohol dependence and schizophrenia.